Pulmonary fungal infections

Respirology

Volumn 17, Issue 6, 2012, Pages 913-926

  Smith, Jeannina A ^a   Kauffman, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

aspergillosis; endemic mycosis; fungal pneumonia; galactomannan test; opportunistic mycosis

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; BLASTOMYCOSIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DRUG EFFICACY; ENZYME IMMUNOASSAY; FUNGAL GENOME; FUSARIOSIS; FUSARIUM; HISTOPLASMOSIS; HUMAN; LUNG ASPERGILLOSIS; LUNG MYCOSIS; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDALLESCHERIASIS; REVIEW; SCEDOSPORIUM;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL; OPPORTUNISTIC INFECTIONS;

EID: 84864446193     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02150.x     Document Type: Review

References (90)

1. Kauffman CA, Nicolasora NP,. Epidemiology of invasive pulmonary aspergillosis. In:, Pasqualotto AC, (ed.) Aspergillosis: From Diagnosis to Prevention. Springer, New York, 2009; 329-44.
2. Pasqualotto AC,. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med. Mycol. 2009; 47: S261-70.
3. van der Linden JWM, Warris A, Verweij PE,. Aspergillus species intrinsically resistant to antifungal agents. Med. Mycol. 2011; 49: S82-9.
4. Cramer RA, Rivera A, Hohl T,. Immune responses against Aspergillus fumigatus: what have we learned? Curr. Opin. Infect. Dis. 2011; 24: 315-22.
5. Singh N, Husain S,. AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am. J. Transplant. 2009; 9 (Suppl. 4): S180-91.
6. Ben-Ami R, Lewis R, Kontoyiannis DP,. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr. Opin. Infect. Dis. 2009; 22: 376-84.
7. Georgiadou SP, Sipsas NV, Marom EM, et al,. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin. Infect. Dis. 2011; 52: 1144-55.
8. Park SY, Kim SH, Choi SH, et al,. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl. Infect. Dis. 2010; 12: 309-15.
9. Segal BH,. Aspergillosis. N. Engl. J. Med. 2009; 360: 1870-84.
10. De Pauw B, Walsh TJ, Donnelly JP, et al,. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008; 46: 1813-21.
11. Maertens J, Theunissen K, Lodewyck T, et al,. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007; 50 (Suppl. 1): 2-17.
12. Pfeiffer CD, Fine JP, Safdar N,. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 2006; 42: 1417-27.
13. Miceli MH, Grazziutti ML, Woods G, et al,. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 2008; 46: 1412-22.
14. Husain S, Kwak EJ, Obman A, et al,. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am. J. Transplant. 2004; 4: 796-802.
15. Clancy CJ, Jaber RA, Leather HL, et al,. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J. Clin. Microbiol. 2007; 45: 1759-65.
16. Husain S, Clancy CJ, Nguyen MH, et al,. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin. Vaccine Immunol. 2008; 15: 1760-3.
17. Guo YL, Chen YQ, Wang K, et al,. Accuracy of bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review. Chest 2010; 138: 817-24.
18. Maertens J, Maertens V, Theunissen K, et al,. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin. Infect. Dis. 2009; 49: 1688-93.
19. Mengoli C, Cruciani M, Barnes RA, et al,. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect. Dis. 2009; 9: 89-96.
20. White LP, Perry MD, Moody A, et al,. Evaluation of analytical and preliminary clinical performance of Myconostica MycAssay Aspergillus when testing serum specimens for diagnosis of invasive aspergillosis. J. Clin. Microbiol. 2011; 49: 2169-74.
21. Luong M-L, Clancy CJ, Vadnerkar A, et al,. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin. Infect. Dis. 2011; 52: 1218-26.
22. Torelli R, Sanguinetti M, Moody A, et al,. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan assay. J. Clin. Microbiol. 2011; 49: 4273-78.
23. Herbrecht R, Denning DW, Patterson TF, et al,. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002; 347: 408-15.
24. Walsh TJ, Anaissie EJ, Denning DW, et al,. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 327-60.
25. Limper AH, Knox KS, Sarosi GA, et al,. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am. J. Respir. Crit. Care Med. 2011; 183: 96-128.
26. Walsh TJ, Raad I, Patterson TF, et al,. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 2007; 44: 2-12.
27. Verweij PE, Snelders E, Kema GHJ, et al,. Azole resistance in Aspergillus fumigatus: a side effect of environmental fungicide use. Lancet Infect. Dis. 2009; 9: 789-95.
28. Howard SJ, Arendrup MC,. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 2011; 49: S90-5.
29. Bowyer P, Moore CB, Rautemaa R, et al,. Azole antifungal resistance today: focus on aspergillosis. Curr. Infect. Dis. Rep. 2011; 13: 485-91.
30. van der Linden JWM, Snelders E, Kampinga GA, et al,. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg. Infect. Dis. 2011; 17: 1846-54.
31. Kontoyiannis DP, Marr KA, Park BJ, et al,. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin. Infect. Dis. 2010; 50: 1091-100.
32. Roden MM, Zaoutis TE, Buchanan WL, et al,. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 2005; 41: 634-53.
33. Kontoyiannis DP, Lionakis MS, Lewis RE, et al,. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 2005; 191: 1350-60.
34. Trifilio S, Singhal S, Williams S, et al,. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007; 40: 451-6.
35. Chamilos G, Marom EM, Lewis RE, et al,. Predictors of pulmonary zygomycosis versus invasive aspergillosis in patients with cancer. Clin. Infect. Dis. 2005; 41: 60-6.
36. Hammond SP, Baden LR, Marty FM,. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob. Agents Chemother. 2011; 55: 5018-21.
37. Chamilos G, Lewis RE, Kontoyiannis DP,. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis. 2008; 47: 503-9.
38. Ibrahim AS, Edwards JE Jr, Filler SG, et al,. Mucormycosis and entomophthoramycosis (zygomycosis). In:, Kauffman CA, Pappas PG, Sobel JD, et al. (eds) Essentials of Clinical Mycology, 2nd edn. Springer, New York, 2011; 265-80.
39. Bialek R, Konrad F, Kern J, et al,. PCR-based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J. Clin. Pathol. 2005; 58: 1180-4.
40. Hammond SP, Bialek R, Milner DA, et al,. Molecular methods to improve the diagnosis and identification of mucormycosis. J. Clin. Microbiol. 2011; 49: 2151-3.
41. Kontoyiannis DP, Lewis R,. How I treat mucormycosis. Blood 2011; 118: 1216-24.
42. Lewis RE, Albert ND, Liao G, et al,. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob. Agents Chemother. 2010; 54: 1298-304.
43. Torres HA, Hachem RY, Chemaly RF, et al,. Posaconazole: a broad spectrum triazole agent. Lancet Infect. Dis. 2005; 5: 775-85.
44. Spellberg B, Walsh TJ, Kontoyiannis DP, et al,. Recent advances in the management of mucormycosis: from bench to bedside. Clin. Infect. Dis. 2009; 48: 1743-51.
45. Torres HA, Kontoyiannis DP,. Hyalohyphomycoses (hyaline molds). In:, Kauffman CA, Pappas PG, Sobel JD, et al. (eds) Essentials of Clinical Mycology, 2nd edn. Springer, New York, 2011; 281-304.
46. Gilgado F, Cano J, Gené J, et al,. Different virulence of the species of the Pseudallescheria boydii complex. Med. Mycol. 2009; 47: 371-4.
47. Rodriquez-Tudela JL, Berenguer J, Guarro J, et al,. Epidemiology and outcome of Scedosporium prolificans infection: a review of 162 cases. Med. Mycol. 2009; 47: 359-70.
48. Husain S, Alexander B, Munoz P, et al,. Opportunistic mycelial fungi in organ transplant recipients: emerging importance of non-Aspergillus mycelial infections. Clin. Infect. Dis. 2003; 37: 221-9.
49. Nucci M, Marr KA, Queiroz-Telles F, et al,. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2004; 38: 1237-42.
50. Nucci M, Anaissie E,. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 2007; 20: 697-704.
51. Nucci M, Anaissie E,. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin. Infect. Dis. 2002; 35: 909-20.
52. Castelli MV, Buitrago MJ, Bernal-Martinez L, et al,. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J. Clin. Microbiol. 2008; 46: 3412-6.
53. Hayden RT, Isotalo PA, Parrett T, et al,. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn. Mol. Pathol. 2003; 12: 21-6.
54. Lortholary O, Obenga G, Biswas P, et al,. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob. Agents Chemother. 2010; 54: 4446-50.
55. Raad II, Hachem RY, Herbrecht R, et al,. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 2006; 42: 1398-403.
56. Ho DY, Lee JD, Rosso F, et al,. Treating disseminated fusariosis: amphotericin B, voriconazole, or both? Mycoses 2007; 50: 227-31.
57. Troke P, Aguirrebengoa K, Arteaga C, et al,. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob. Agents Chemother. 2008; 52: 1743-50.
58. Steinbach WJ, Perfect JR,. Scedosporium species infections and treatments. J. Chemother. 2003; 15: 16-27.
59. Harris JR, Lockhart SR, Debess E, et al,. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin. Infect. Dis. 2011; 53: 1188-95.
60. Pappas PG, Perfect JR, Cloud GA, et al,. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 2001; 33: 690-9.
61. Singh N, Dromer F, Perfect JR, et al,. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin. Infect. Dis. 2011; 47: 1321-7.
62. Chang WC, Tzao C, Hsu HH, et al,. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 2006; 129: 333-40.
63. Baddley JW, Perfect JR, Oster RA, et al,. Pulmonary cryptococcosis in patients without HV infection: factors associated with disseminated disease. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 937-43.
64. Singh N, Forrest G, Infectious AST,. Diseases Community of Practice. Cryptococcosis in solid organ transplant recipients. Am. J. Transplant. 2009; 9 (Suppl. 4): S192-8.
65. Perfect JR, Dismukes WE, Dromer F, et al,. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2010; 50: 291-322.
66. Saccente M, Woods GL,. Clinical and laboratory update on blastomycosis. Clin. Microbiol. Rev. 2010; 23: 367-81.
67. Smith JA, Kauffman CA,. Blastomycosis. Proc. Am. Thorac. Soc. 2010; 7: 173-80.
68. Lemos LB, Baliga M, Guo M,. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann. Diagn. Pathol. 2001; 5: 1-9.
69. Martynowicz MA, Prakash UB,. Pulmonary blastomycosis: an appraisal of diagnostic techniques. Chest 2002; 121: 768-73.
70. Durkin M, Witt J, Lemonte A, et al,. Antigen assay with the potential to aid in diagnosis of blastomycosis. J. Clin. Microbiol. 2004; 42: 4873-5.
71. Bariola JR, Hage CA, Durkin M, et al,. Detection of Blastomyces dermatitidis antigen in patients with newly diagnosed blastomycosis. Diagn. Microbiol. Infect. Dis. 2011; 69: 187-91.
72. Carlos WG, Rose AS, Wheat LJ, et al,. Blastomycosis in Indiana: digging up more cases. Chest 2010; 138: 1377-82.
73. Babady NE, Buckwalter SP, Hall L, et al,. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J. Clin. Microbiol. 2011; 49: 3204-8.
74. Chapman SW, Dismukes WE, Proia LA, et al,. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 1801-12.
75. Lahm T, Neese S, Thornburg AT, et al,. Corticosteroids for blastomycosis-induced ARDS; a report of two patients and review of the literature. Chest 2008; 133: 1478-80.
76. Kauffman CA,. Histoplasmosis: clinical and laboratory update. Clin. Microbiol. Rev. 2007; 20: 115-32.
77. Wheat LJ, Conces D, Allen SD, et al,. Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Sem. Respir. Crit. Care Med. 2004; 25: 129-44.
78. Wheat LJ,. Approach to the diagnosis of the endemic mycoses. Clin. Chest Med. 2009; 30: 379-89.
79. Swartzentruber S, Rhodes L, Kurkjian K, et al,. Diagnosis of acute pulmonary histoplasmosis by antigen detection. Clin. Infect. Dis. 2009; 49: 1878-82.
80. Hage CA, Davis TE, Fuller D, et al,. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest 2010; 137: 623-8.
81. Hage CA, Ribes JA, Wengenack NL, et al,. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin. Infect. Dis. 2011; 53: 448-54.
82. Wheat LJ, Freifeld AG, Kleiman MB, et al,. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2007; 45: 807-25.
83. Freifeld A, Proia L, Andes D, et al,. Voriconazole use for endemic fungal infections. Antimicrob. Agents Chemother. 2009; 53: 1648-51.
84. Doyle TP, Loyd JE, Robbins IM,. Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am. J. Respir. Crit. Care Med. 2001; 164: 657-60.
85. Ampel NM,. Coccidioidomycosis. In:, Kauffman CA, Pappas PG, Sobel JD, et al. (eds) Essentials of Clinical Mycology, 2nd edn. Springer, New York, 2011; 349-66.
86. Anstead GM, Graybill JR,. Coccidioidomycosis. Infect. Dis. Clin. North Am. 2006; 20: 621-43.
87. Pappagianis D,. Current status of serologic studies in coccidioidomycosis. Curr. Fungal Infect. Rep. 2007; 1: 129-34.
88. Durkin M, Connolly P, Kuberski T, et al,. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay. Clin. Infect. Dis. 2008; 47: e69-73.
89. Galgiani JN, Ampel NM, Blair JE, et al,. Coccidioidomycosis. Clin. Infect. Dis. 2005; 41: 1217-23.
90. Kim MM, Vikram HR, Kusne S, et al,. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin. Infect. Dis. 2011; 53: 1060-6.